Dx Dialogues: Metabolic-associated steatohepatitis (MASH)
- Dx Dialogues
- Dx Dialogues: Metabolic-associated steatohepatitis (MASH)
Medically reviewed in July 2024
Aja McCutchen, MD, of Atlanta Gastroenterology, discusses the primary factors driving the epidemic of metabolic-associated steatohepatitis (MASH) and the significantly elevated risk of liver complications associated with the disease. Dr. McCutcheon also highlights recent advances in diagnosis and treatment, and trial results for the first FDA-approved therapy.
Transcript
Featured Content
Article
MASH: The Silent Epidemic of Metabolic Liver Disease15 million people in the U.S. with MASH face increased risk of cirrhosis, hepatocellular carcinoma and liver transp...
Article
New Frontiers in MASH: Emerging Tools for Liver Assessment and DiagnosisDiagnosing MASH requires a liver biopsy, but less invasive methods are on the horizon.
Article
Expanding Treatment Options for MASH: New Options and Emerging TherapiesTreatment for MASH expands to FDA-approved pharmacotherapy with others in clinical trials.
Article
FDA Approves First-Ever Therapy for MASH with fibrosisFor the first time, patients with non-alcoholic steatohepatitis with scarring have an approved therapy.
